- Home
- DOYU vs MIST Comparison
DOYU vs MIST Comparison
Compare DOYU & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOYU | MIST |
|---|---|---|
| Founded | 2014 | 2003 |
| Country | China | Canada |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.4M | 176.3M |
| IPO Year | 2019 | 2019 |
Fundamental Metrics
Financial Performance| Metric | DOYU | MIST |
|---|---|---|
| Price | $5.11 | $1.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $7.00 | ★ $8.50 |
| AVG Volume (30 Days) | 52.5K | ★ 1.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.80 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.28 | $0.63 |
| 52 Week High | $9.93 | $3.06 |
Technical Indicators
Market Signals| Indicator | DOYU | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 41.54 | 45.65 |
| Support Level | $4.28 | $1.62 |
| Resistance Level | $7.11 | $1.79 |
| Average True Range (ATR) | 0.39 | 0.07 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 57.81 | 70.00 |
Price Performance
Historical ComparisonAbout DOYU DouYu International Holdings Limited ADS
DouYu International Holdings Ltd is a game-centric live streaming platform in China and a pioneer in the eSports value chain. The company operates its platform on both PC and mobile apps, through which users can enjoy immersive and interactive games and entertainment live streaming. It generates revenues through live streaming and advertisement.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).